Franklin Genomic Advancements ETF
HELX
8 hedge funds and large institutions have $1.16M invested in Franklin Genomic Advancements ETF in 2022 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 2 closing their positions.
27% less funds holding
Funds holding: 11 → 8 (-3)
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
85% less capital invested
Capital invested by funds: $7.53M → $1.16M (-$6.36M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
123.73% less ownership
Funds ownership: 155.21% → 31.48% (-124%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BFEC
Benjamin F. Edwards & Company
St. Louis,
Missouri
|
+$31.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$26.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$4.09M |
| 2 |
FTUS
Flow Traders U.S.
New York
|
-$315K |
| 3 |
LPL Financial
San Diego,
California
|
-$238K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$167K |
| 5 |
SWM
Spire Wealth Management
Mclean,
Virginia
|
-$61.8K |
HELX Hedge Fund Activity: Q1 2022 in Review
8 of the 6,361 institutional investors tracked by Wall St. Rank reported a position in Franklin Genomic Advancements ETF (HELX) for Q1 2022, worth a combined $1.16M — down 85% from $7.53M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of HELX and 0 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 2 added.
The largest buyer was Benjamin F. Edwards & Company, adding an estimated $31.1K. The largest seller was Jane Street, cutting an estimated $4.09M.
- 8 institutional investors held Franklin Genomic Advancements ETF (HELX) as of Q1 2022, down from 11 in Q4 2021.
- Funds reported $1.16M of Franklin Genomic Advancements ETF stock for Q1 2022, down 85% quarter-over-quarter.
- 0 funds opened new Franklin Genomic Advancements ETF positions in Q1 2022 and 2 closed out, a net change of -2 holders.
- The largest Franklin Genomic Advancements ETF buyer in Q1 2022 was Benjamin F. Edwards & Company, an estimated $31.1K added.
- The largest Franklin Genomic Advancements ETF seller in Q1 2022 was Jane Street, an estimated $4.09M sold.
Based on aggregated 13F filings for Q1 2022.